(NYSEMKT: AEON) Aeon Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.18%.
Aeon Biopharma's earnings in 2026 is -$54,623,000.On average, 3 Wall Street analysts forecast AEON's earnings for 2026 to be -$19,843,374, with the lowest AEON earnings forecast at -$19,065,202, and the highest AEON earnings forecast at -$20,427,003.
In 2027, AEON is forecast to generate -$26,966,636 in earnings, with the lowest earnings forecast at -$25,909,121 and the highest earnings forecast at -$27,759,773.